Cardiovascular and limb outcomes with SGLT2 inhibitors in patients with diabetes following peripheral endovascular therapy.
SGLT2 inhibitors reduce heart complications in diabetic patients with peripheral artery disease without increasing amputation risk.
In 470 DM+PAD patients following successful peripheral endovascular therapy followed for median 4 years, SGLT2 inhibitor use was independently associated with lower MACE risk after propensity matching, with no increased limb amputation or revascularization events. The consistent benefit across frailty and comorbidity subgroups strengthens the case for SGLT2i in this high-cardiovascular-risk PAD population.
What the study was
- Study design
- Retrospective cohort with propensity score matching
- Population
- Diabetic patients with PAD undergoing peripheral endovascular therapy
- Sample size
- 470
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Cardiology
Why it surfaced
SGLT2i CV benefit in PAD patients after revascularization is clinically relevant for treatment optimization in a high-risk population underserved by prior trial data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.